The EAGLE study: two is not always better than one

Affiliations

Editorial

M C Merlano. Ann Oncol. 2020 Jul.

. 2020 Jul;31(7):830-831.

doi: 10.1016/j.annonc.2020.04.474. Epub 2020 May 7.

¹ Department of Medical Oncology, Candiolo Cancer Center FPO - IRCCS, Candiolo, Torino, Italy. Electronic address: mcmerlano@gmail.com.

No abstract available

Conflict of interest statement

Funding No funding was received. Disclosure The author has declared no conflicts of interest.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Ferris RL, et al. Ann Oncol. 2020 Jul;31(7):942-950. doi: 10.1016/j.annonc.2020.04.001. Epub 2020 Apr 12. Ann Oncol. 2020. PMID: 32294530 Clinical Trial.